Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P.D. King, M.C. Perry.
Hepatotoxicity of chemotherapeutic and oncologic agents.
Gastroenterol Clin North Am, 24 (1995), pp. 969-990
[2.]
T.A. Goodman, R.P. Polisson.
Methotrexate: adverse reactions and major toxicities.
Rheum Dis Clin North Am, 20 (1994), pp. 513-529
[3.]
A. Schnabel, W.L. Gross.
Low-dose methotrexate in rheumatic disease-efficacy, side effects, and risk factors for side effects.
Sem Arthritis Rheum, 23 (1994), pp. 310-327
[4.]
R.J.R. McKendry, P. Dale.
Adverse effects of low dose methotrexate therapy in rheumatoid arthritis.
J Rheumatol, 20 (1993), pp. 1850-1856
[5.]
A.M. Walker, D. Funch, N.A. Dreyer, K.G. Tolman, J.M. Kremer, G.S. Alarcón, et al.
Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis.
Arthritis Rheum, 36 (1993), pp. 329-335
[6.]
C.A. Phillips, P.J. Cera, T.F. Mangan, E.D. Newman.
Clinical liver disease in patients with rheumatoid arthritis taking methotrexate.
J Rheumatol, 19 (1992), pp. 229-233
[7.]
J.M. Kremer, R.G. Lee, K.G. Tolman.
Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy.
Arthritis Rheum, 32 (1989), pp. 121-127
[8.]
A.R. Erickson, V. Reddy, S.A. Vogelgesang, S.G. West.
Usefulness of american college of rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients.
Arthritis Rheum, 38 (1995), pp. 115-119
[9.]
J.M. Kremer.
Liver biopsies in patients with rheumatoid arthritis receiving methotrexate: where are we going?.
J Rheumatol, 19 (1992), pp. 189-191
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
